Page - Home
Treatment with Varumin®
Sibin Ilic, MD, PhD Expert for oncology and gynaecology - 12.10.1999
Based on many year experience with the supplementary medical treatment by Varumin®,
I think that this preparation has the favorable subjective and objective effects and that it can be applied
without any therapy risks at oncological and immune-deficient patients
Stojmir Petrov, MD, PhD Department of Preclinical and Clinical Pharmacology and Toxicology
- Medical Faculty, Skopje Republic of Macedonia - 09.01.2006 -
The active ingredients of the product have laxative, anti-inflammatory, anti-microbe,
immune-stimulative, detoxifi-cative, cytotoxic, diuretic, anti-depressive and other actions.
These pharmaco-dynamic characteristics of the compounds of Varumin® justified the purposed field of action.
D-r D.Petrovski (Spec. Neuro-psychiatrist); Primarius D-r T.Hristovski (Spec. Neuro-psychiatrist);
Primarius K.Petrovski (Spec. neurologist and psychiatrist); D-r K.Pili-Kuzeva (Spec. Neuro-psychiatrist);
Efficiency and safety of Varumin® in treatment of Sclerosis Multiplex (MS)
– Clinical Hospital Bitola – Department of Neurology – 2007
From the whole trial we can make conclusion that at all patients have visible improvement of the general condition and neurological functions.
Improvement of the functionality. Efficiency of Varumin® was established after the second month
and it is continuous during the whole therapy. Varumin® has excellent safety profile.
Ass. D-r G. Dimitrov (Gynecology Specialist), D-r M. Risteski (Oncology Specialist)
Clinical trial on terapeutic efficacy, tolerability and safety of peroral solutions Varumin® 1 and 2 with biologicaly proven high risk type HPV infection, with or without biopsy proven CIN I.
University Clinic of Gynecology and Obstetrics Skopje, University St. Cyrillus and Methodius, Skopje – 2009
Our conclusion is that this tested product has favourable participation in high-risk type HPV lesion treatment. Time needed for negative
utilization of HPV PCR type is shorten. Percentage of normalized colposcopic and PAP findings is much greater to the group treated with
this tested product. In relation of security, for this tested product we consider and assess its safety and also as an independent treatment as well.